DENVER BUSINESS JOURNAL - A Boulder biotech that's exploring gene-editing technology said it's raised $55.5 million in a Series C round of funding.

Inscripta, which used to be known as Muse Biotechnology, said the latest funding round was led by Mérieux Développement and Paladin Capital Group. Additional participants included all previous Inscripta investors: Venrock, Foresite, MLS Capital, and NanoDimension.

The fundraising comes just a year after Muse bio raised $23 million in a Series B round of funding.

The latest round of funding, said CEO Kevin Ness, will hire additional scientists.

Read more about this story at the Denver Business Journal.